» Articles » PMID: 34674310

The Effect of Granulocyte Colony-stimulating Factor Dose and Administration Interval After Allogeneic Hematopoietic Cell Transplantation on Early Engraftment of Neutrophil and Platelet

Overview
Journal J Clin Lab Anal
Publisher Wiley
Date 2021 Oct 21
PMID 34674310
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hematopoietic stem cell transplantation (HSCT) is one of the treatments for hematologic malignancies. Numerous factors affect the HSCT outcome. The purpose of this study was to investigate the effect of post-HSCT administration of granulocyte colony-stimulating factor (post-G-CSF) on early neutrophil and platelet engraftment in allogeneic HSCT (allo-HSCT).

Material & Methods: The study was performed on 76 patients diagnosed with AML and ALL. All patients underwent allo-HSCT at Taleghani stem cell transplantation center, Tehran, Iran, from February 2016 to December 2018. Chemotherapy regimens based on patients' conditions were selected between myeloablative and reduced-intensity regimens.

Results: Statistical analysis revealed that the number of administered G-CSF units after HSCT was a time-dependent variable. Statistical analysis before day +11 reported that patients who received G-CSF <14 units had three times better early neutrophil engraftment than those with G-CSF ≥14 (CI 95%, AHR = 3.03, p:0.002). CD3+ cells count <318.5 × 10 /kg was associated with fast platelet engraftment (CI 95%, AHR 2.28, p:0.01).

Conclusion: In this study, post-G-CSF stimulation was associated with early engraftment in a time- and dose-dependent manner. Administration of G-CSF beyond 14 units resulted in adverse effects on neutrophil early engraftment. It also appeared that with a reduction in CD3+ cell counts, the likelihood of GVHD decreases, and platelet engraftment occurs earlier. Further investigations in the future are required to determine the factors affecting the process of early engraftment.

Citing Articles

The effect of granulocyte colony-stimulating factor dose and administration interval after allogeneic hematopoietic cell transplantation on early engraftment of neutrophil and platelet.

Noorazar L, Bonakchi H, Sankanian G, Parkhideh S, Salimi M, Hajifathali A J Clin Lab Anal. 2021; 35(12):e24060.

PMID: 34674310 PMC: 8649331. DOI: 10.1002/jcla.24060.

References
1.
Miflin G, Russell N, Hutchinson R, MORGAN G, Potter M, Pagliuca A . Allogeneic peripheral blood stem cell transplantation for haematological malignancies--an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant. 1997; 19(1):9-13. DOI: 10.1038/sj.bmt.1700603. View

2.
Bishop M, Tarantolo S, Geller R, Lynch J, Bierman P, Pavletic Z . A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000; 96(1):80-5. View

3.
Mato A, Morgans A, Luger S . Novel strategies for relapsed and refractory acute myeloid leukemia. Curr Opin Hematol. 2008; 15(2):108-14. DOI: 10.1097/MOH.0b013e3282f463d2. View

4.
Ardakani M, Mehrpooya M, Mehdizadeh M, Beiraghi N, Hajifathali A, Kazemi M . Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplant. 2019; 55(4):830-832. DOI: 10.1038/s41409-019-0623-0. View

5.
Parkhideh S, Chegeni R, Mehdizadeh M, Roshandel E, Tavakoli F, Hajifathali A . Effects of ABO incompatibility on the outcome of allogeneic hematopoietic stem cell transplantation. Transfus Apher Sci. 2019; 59(2):102696. DOI: 10.1016/j.transci.2019.102696. View